An Alzheimer's Blood Test Is Now Being Used on Real Patients — What Each Result Actually Means

Alzheimer’s blood tests have moved out of the research lab. Memorial Health System in Owosso, Michigan says it began testing patients on October 22, 2026 with Roche’s Elecsys pTau217 — and describes itself as the first U.S. laboratory to use this test on patients (that “first” is Memorial’s own claim, not independently confirmed). As of November 2026, four Alzheimer’s blood tests have been cleared by the FDA. Here is what this one is for, who it is not for, and what each possible result actually means.

Who the test is for

The Elecsys pTau217 test, cleared by the FDA on August 19, 2026 (Roche announced the clearance August 24), is indicated for adults 55 and older who have signs, symptoms, or complaints of cognitive decline, in primary and specialty care settings. It is explicitly not for people without symptoms: testing someone with no cognitive complaints is still not recommended, and a result in a person without symptoms does not carry the same meaning.

What it measures — and what it does not

The test measures plasma p-tau217, a marker associated with the amyloid pathology seen in Alzheimer’s disease. It returns results in tiers — positive, intermediate, and negative. An intermediate result means confirmatory testing is needed. No tier, on its own, diagnoses Alzheimer’s disease; the test supports a diagnostic workup, it does not replace one.

Why a blood test matters

Until now, confirming amyloid pathology has usually meant a PET scan or a spinal tap for cerebrospinal fluid — costly, invasive, and hard to schedule in many areas. Roche’s framing is that a blood draw lowers that barrier. Keep the attribution in mind: easier confirmation is the manufacturer’s case for the test, and your clinician still decides whether testing fits your situation.

Access reality

Memorial has not published price or insurance details, so ask the ordering office and your insurer what a test would cost you before agreeing to one. Wider access is coming: Labcorp and Quest both announced on August 24 that they plan to offer the test nationally, with Quest targeting a Q4 2026 service launch.

Questions to ask before and after testing

• Before: Am I in the group this test is cleared for (55+, with cognitive symptoms)? What will it cost, and does my insurance cover it?
• On an intermediate result: what confirmatory test comes next, and who orders it?
• On a positive result: what does this unlock — and what does it not? Eligibility for Alzheimer’s treatments is a separate workup; a blood test result alone does not qualify or disqualify anyone.
• On a negative result: what else could explain the symptoms, and what follow-up is planned?

Key Takeaways

• Roche’s Elecsys pTau217 was FDA-cleared August 19, 2026 for adults 55+ with cognitive symptoms; it is not for people without symptoms and does not diagnose Alzheimer’s on its own.
• Memorial Health System (Owosso, MI) reports it began patient testing October 22, 2026, describing itself as the first U.S. lab to do so — its own claim.
• Results come as positive, intermediate (confirmatory testing needed), or negative.
• Labcorp and Quest have announced plans to offer the test nationally; no price/insurance details are published — ask before you test.